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Abstract 
Back ground: The World Health Organization (WHO) declared Tuberculosis a global health 
emergency in 1993 as it remains a major cause of mortality in developing countries. The World 
Health Organization's Directly Observed Treatment Short course (DOTs) strategy achieve 87% 
success rate in the areas where it is implemented, usually with five drugs, lasts for 6months. Till 
1998 Sudan was classified as one of the slowly moving countries in implementation of the DOTS 
strategy and making no progress against tuberculosis.
Objective: A prospective comparative, randomized clinical trial, hospital based study carried out at 
Kosti Teaching Hospital using directly observed treatment short course (DOTS), to assess the 
adverse drug reactions of intermittent chemotherapy compared to the currently adopted short course 
therapy. 
Methodology: Patients with smear positive new cases of tuberculosis were enrolled and 
randomized  in to two groups, intermittent treatment group (A) and daily regimen group (B) .The 
raw data were introduced into SPSS program, the data comparison was carried out by Pearson Chi 
square and pair independent sample student T-test. The level of significance (P<0.05). 
Results: A total of 275 were studied, significant initial (pre-interventional) elevated means of 
aspartate aminotransferase (AST) was detected in the two groups and significantly in the 
intermittent regimen after two and four months, but the decrease was significant only after two 
months in the daily group.  
Conclusion: Liver injury following antituberculous treatment was minimal and the adverse drug 
reactions were tolerable concerning the majority of the patients completing the course of the 
treatment.   
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he World Health Organization (WHO) 
declared Tuberculosis a global health 
emergency in 19931 as it remains a 
major cause of mortality in developing 
countries2. The World Health Organization's 
Directly Observed Treatment Short course 
(DOTs) strategy achieve 87% success rate in 
the areas where it is implemented, usually 
with five drugs, lasts for 6months. Till 1998 
Sudan was classified as one of the slowly 
moving countries in implementation of the 
DOTS  
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strategy and making no progress against 
tuberculosis3. In 2002, DOTS was declared all 
over the country by Sudan National 
Tuberculosis Programme Progress Report 
20054.
Concerning the pharmacokinetics of INH, it 
is rapidly absorbed from gastrointestinal tract, 
highly diffuses to body tissues and body 
fluids, metabolized  through acetylation, 
which depends on genetic variations either 
rapid acetylators or fast acetylators5. As far as 
can be ascertained a study addressing the 
adverse drug reactions has not been 
conducted in Sudan,  therefore,  assessment of 
the safety of  antituberculous drugs is and 
highly needed . 
T
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Material and Methods:
This is a prospective comparative, 
randomized clinical trial, hospital based study 
was carried out in Kosti Teaching Hospital.  
Set up: Kosti Teaching hospital is the major 
referral hospital of the White Nile State which 
is inhabited by different ethnic groups, 15 
tuberculosis centers were initiated in the state 
by the local tuberculosis control program.  
New smear positive pulmonary tuberculosis 
patients who attended the department of chest 
at Kosti Teaching Hospital during March 
2006 to March 2008 were enrolled in this 
study. 
The inclusion criteria were as follows: 
1. Adult > 15 years old. 
2. Three samples sputum smear positive 
pulmonary case. 
3. Absence of associated debilitating 
diseases or advanced disseminated cases.   
According to Eldahian6, the minimum sample 
size was calculated as 226 patients, but 275 
patients were introduced then randomized 
using lottery into two groups: 
1. Group (A) the intermittent regimen group 
(128 patients)  these patients were treated 
using Ethambutol (20mg/kg), Rifampicin 
(10mg\kg)\ Isoniazid (6mg/kg) and 
Pyrazinamide (25mg/kg) for two months 
as an initial phase then were given the 
minimum intermittent dosage of 
rifampicin 900mg (30mg/kg)\ isoniazid 
450mg (15mg/kg) twice weekly (about 12 
tablets\week) for four additional months.  
2. Group (B), the short course daily regimen 
group (147 patients) were treated using 
streptomycin (15mg), rifampicin 
(10mg/kg)\ isoniazid (6mg/kg) and 
pyrazinamide (25mg/kg) for two months 
as an initial phase then rifampicin 
(10mg/kg)\ isoniazid (6mg/kg)  once daily 
(about 21 tablets\ week) for four 
additional months.  
Liver functions were assessed by 
spectrophotometrical assay of Alanine 
Amino-transferase (ALT) and Aspartate 
Amino-transferase (AST) enzymes according 




The raw data were introduced into SPSS 
program for the performance of the 
descriptive and comparative analysis. The 
data comparison was carried out by Pearson 
Chi square and pair independent sample 
student T-test. The level of significant was 
taken at (P<0.05). 
Ethical consideration: 
A written consent from the local health 
authority was taken and each patient was 
informed and consented. Patients who do not 
agreed were excluded keeping their right of 
receiving free drugs, sputum investigation, 




A total of 275 patients were included in this 
study. Out of them males comprise 55%. 
Their mean age was illustrated in Fig 1 and 
the levels of ALT before and after treatment 
for the two groups were dipicted in tables 1 
and 2. Considering the educational level, it 
was found that about 59% of the entered 
patients were illiterate.   
Treatment discontinuation due to Rifampicin 
induced jaundice and hypersensitivity was 
deselected in 0.7% (one patient) in group B, 
the patient was excluded although she 
recovered after rifampicin was stopped. 
Drug- induced jaundice occurred in one (4%) 
of the patients in group A and 3% in group B. 
Flu like syndrome was not identified. 
 
Discussion: 
A descriptive and comparative designs were 
used, (275 patients) were enrolled in the study 
where 55 % of them   were males and 45% 
were females, The male to female ration  is 
not comparable  to other studies stated by 
Mohammed and coworker 2007 in South 
Africa 56% females, 44% males respectively8
and nearly similar to the results obtained by 
Muhan and coworker 2007  in Pakistan 54 
males and 46 females9.
In general the Sudan National   Tuberculosis 
Program stated that the number of the 
infected males and females is nearly equal10.
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P-value = 0.723 
 
Figure (1): Age and sex distribution of the study population (group A and B) N = 275 patients 
 








Group A Group B 
Value P-Value No % No % No % 
initial ALT 
(pretreatment) 
Normal 56 78.9% 58 86.6% 114 82.6% 
1.420 0.233 
Elevated 15 21.1% 9 13.4% 24 17.4% 
ALT after 2 
months 
Normal 57 80.3% 58 86.6% 115 83.3% 0.981 0.322 
Elevated 14 19.7% 9 13.4% 23 16.7% 
ALT after 
4months 
Normal 62 87.3% 60 89.6% 122 88.4% 
0.167 0.683 Elevated 9 12.7% 7 10.4% 16 11.6% 
Normal value > 35 units \ liter 
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AST  Group A Group B Value P-Value 
No % No % No % 
Initial AST 
(pretreatment) 
Normal 33 46.5% 41 61.2% 74 53.6% 3.001 0.083 Elevated 38 53.5% 26 38.8% 64 46.4% 
AST after 2 
months 
Normal 51 71.8% 47 70.1% 98 71.0% 
0.047 0.828 Elevated 20 28.2% 20 29.9% 40 29.0% 
AST after 4 
months 
Normal 60 84.5% 49 73.1% 109 79.0% 
2.686 0.101 Elevated 11 15.5% 18 26.9% 29 21.0% 
Considering the educational level, it was 
found that about 59 % of the entered patients 
were illiterate, which is higher than the 
percentage mentioned by Sudan National  
Tuberculosis Program 27.3%  were illiterate 
in Khartoum state10,Generally it is known that 
the  tuberculous infection rate is inversely 
proportional to the educational level (figure 
3.2). Treatment discontinuation due to 
hepatitis as a result of rifampicin 
hypersensitivity was detected in 0 .7 % (one 
patient) in group B, the patient was excluded 
although she was recovered after rifampicin 
was stopped. 
Drug-induced jaundice occurred in 1, 4% of 
the patients in group A and 3% in group but,  
these patients recovered after stopping the 
treatment for a week then treatment continued 
without any problem. 
Flu like syndrome was not identified which 
usually limits the use of Rifampicin 
dependent intermittent regimen and many 
investigators describe the syndrome. In India 
according to Rajinder Singh Bedi and 
coworkers, Flu like Syndrome due to 
ethambutol, the flu syndrome has usually 
associated with intermittent (rarely daily) use 
of Rifampicin, though a case of Ethambutol-
induced11. Flu like syndrome was identified, 
and three cases of flu like symptoms due to 
Isoniazid were found in 1989. The findings 
are also different from the fact stated by 
James and coworker that flu like is a common 
adverse drug reaction of rifampicin dependent 
regimen12, also different from Gerald K. Mc 
Evoy and coworker 1988 who mentioned that 
Flu like syndrome was been associated with 
the use of twice a week intermittent 
rifampicin and identified in 1% of the 
patients13.
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